# US 2014/0155731 A1 · Method for identifying neuroprotective compounds and/or neuroregeneration stimulators by fractional anisotropy measurements by diffusion-based mri scanning

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0155731 A1
- Document ID: US20140155731A1
- Status: Published application
- Kind: A1
- Application number: 14/119,226
- Filed: 2012-05-23
- Published: 2014-06-05
- Earliest claimed: 2011-05-23
- Assignees: Assistance Publique-Hopitaux de Paris
- Inventors: Louis Puybasset; Damien Galanaud; Habib Benali; Vincent Perlbarg; Stéphane Lehericy
- Web page: https://patentgrep.com/patent/US20140155731A1

## CPC

- A61B 5/4848: {Monitoring or testing the effects of treatment, e.g. of medication}
- A61B 5/0042: {for the brain}
- A61B 5/055: involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
- A61B 5/7225: {Details of analogue processing, e.g. isolation amplifier, gain or sensitivity adjustment, filtering, baseline or drift compensation (input circuits for detecting, measuring, or recording bioelectric or biomagnetic signals A61B5/30; specific diagnostic methods using bioelectric or biomagnetic signals A61B5/316)}
- G01R 33/485: based on chemical shift information {[CSI] or spectroscopic imaging, e.g. to acquire the spatial distributions of metabolites}
- G01R 33/56341: {Diffusion imaging}
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- G01R: MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES (indicating correct tuning of resonant circuits H03J3/12)

## Abstract

The present invention relates to a method for monitoring the effectiveness of a treatment on neuroprotection and to a method for identifying candidate molecules that are neuroprotectors and/or neuronal growth stimulators. The present invention can be used, in particular, in the field of pharmaceutics, in the field of scientific research and in the field of clinical trials and validation of therapeutic substances.

## Claims

### Claim 1

A method for monitoring the effectiveness of a treatment on neuroprotection comprising:
a) measurement of the fractional anisotropy FA1 in at least one region of interest of the brain on an image obtained by Magnetic Resonance Imaging (MRI) of the brain of a patient before said treatment,
b) measurement of the fractional anisotropy FA2 of said at least one region of interest of the brain on an MRI imaging of the brain of said patient after said treatment,
c) comparison of the fractional anisotropy values and calculation of a score (S) according to the following formula:
S=FA2/FA1,
a value of S greater than 1.08 indicating that the treatment is a neuroprotective and/or neural growth stimulator treatment.

### Claim 2 (depends on 1)

The method as claimed in claim 1, also comprising a step d) of measuring the axial diffusivity, radial diffusivity, mean diffusivity, and apparent diffusion co efficient.

### Claim 3 (depends on 1)

The method as claimed in claim 1, wherein the measurements of fractional anisotropy of steps a) and b) are performed in at least one of the regions of interest of the brain chosen from the middle cerebellar peduncle (ICBM #1), the anterior brain stem (ICBM #2,7,8), the posterior brain stem (ICBM #9,10,11,12,13,14), the genu of the corpus callosum (ICBM #3), the body of the corpus callosum (ICBM #4), the splenium of the corpus callosum (ICBM #5), the right cerebral peduncle (ICBM #15), the left cerebral peduncle (ICBM #16), the right sagittal stratum (ICBM #21,29,31,47), the left sagittal stratum (ICBM #22,30,32,48), the right superior longitudinal fascicle (ICBM #41), the left superior longitudinal fascicle (ICBM #42), the anterior limb of the right internal capsule (ICBM #17), the anterior limb of the left internal capsule (ICBM #18), the posterior limb of the right internal capsule (ICBM #19), the posterior limb of the left internal capsule (ICBM #20), the right external capsule (ICBM #33), the left external capsule (ICBM #34), the right radiate crown (ICBM #23,25,27), the left radiate crown (ICBM #24,26,28).

### Claim 4 (depends on 1)

The method as claimed in claim 1, wherein the measurements of fractional anisotropy of steps a) and b) are performed in the regions of interest of the brain chosen from the middle cerebellar peduncle (ICBM #1), the anterior brain stem (ICBM #2,7,8), the posterior brain stem (ICBM #9,10,11,12,13,14), the genu of the corpus callosum (ICBM #3), the body of the corpus callosum (ICBM #4), the splenium of the corpus callosum (ICBM #5), the right cerebral peduncle (ICBM #15), the left cerebral peduncle (ICBM #16), the right sagittal stratum (ICBM #21,29,31,47), the left sagittal stratum (ICBM #22,30,32,48), the right superior longitudinal fascicle (ICBM #41), the left superior longitudinal fascicle (ICBM #42), the anterior limb of the right internal capsule (ICBM #17), the anterior limb of the left internal capsule (ICBM #18), the posterior limb of the right internal capsule (ICBM #19), the posterior limb of the left internal capsule (ICBM #20), the right external capsule (ICBM #33), the left external capsule (ICBM #34), the right radiate crown (ICBM #23,25,27), the left radiate crown (ICBM #24,26,28).

### Claim 5 (depends on 1)

The method as claimed in claim 1, wherein the measurement of fractional anisotropy is performed on an MRI image of a patient having suffered a cerebral legion, including cranial trauma, aneurismal meningeal hemorrhagic, ischemic and intraparenchymal hemorrhagic accidents, cerebral anoxia.

### Claim 6 (depends on 5)

The method as claimed in claim 5, wherein the measurement of FA1 is performed on an MRI image taken in a period of 48 hours to 31 days following the brain lesion.

### Claim 7 (depends on 1)

The method as claimed in claim 1, wherein the measurement of FA2 is performed on an MRI image taken in a period of at least one month following the measurement of FA1.

### Claim 8

A method for identifying a neuroprotective and/or neural growth stimulative candidate molecule comprising:
a) measurement of the fractional anisotropy FA1 in at least one region of interest of the brain on an image obtained by Magnetic Resonance Imaging (MRI) of the brain of a patient before said treatment,
b) measurement of the fractional anisotropy FA2 of said at least one region of interest of the brain on an MRI imaging of the brain of said patient after said treatment,
c) comparison of the fractional anisotropy values and calculation of a score (S) according to the following formula:
S=FA2/FA1,
a value of S greater than or equal to 1.08 indicating that the candidate molecule is neuroprotective and/or neural growth stimulative.

### Claim 9 (depends on 8)

The method as claimed in claim 8, in which the measurements of fractional anisotropy of steps a) and b) are performed in at least one of the regions of interest of the brain chosen from the middle cerebellar peduncle (ICBM #1), the anterior brain stem (ICBM #2,7,8), the posterior brain stem (ICBM #9,10,11,12,13,14), the genu of the corpus callosum (ICBM #3), the body of the corpus callosum (ICBM #4), the splenium of the corpus callosum (ICBM #5), the right cerebral peduncle (ICBM #15), the left cerebral peduncle (ICBM #16), the right sagittal stratum (ICBM #21,29,31,47), the left sagittal stratum (ICBM #22,30,32,48), the right superior longitudinal fascicle (ICBM #41), the left superior longitudinal fascicle (ICBM #42), the anterior limb of the right internal capsule (ICBM #17), the anterior limb of the left internal capsule (ICBM #18), the posterior limb of the right internal capsule (ICBM #19), the posterior limb of the left internal capsule (ICBM #20), the right external capsule (ICBM #33), the left external capsule (ICBM #34), the right radiate crown (ICBM #23,25,27), the left radiate crown (ICBM #24,26,28).

### Claim 10 (depends on 8)

The method as claimed in claim 8, wherein the measurements of fractional anisotropy of the steps a) and b) are performed in the regions of interest of the brain chosen from the middle cerebellar peduncle (ICBM #1), the anterior brain stem (ICBM #2,7,8), the posterior brain stem (ICBM #9,10,11,12,13,14), the genu of the corpus callosum (ICBM #3), the body of the corpus callosum (ICBM #4), the splenium of the corpus callosum (ICBM #5), the right cerebral peduncle (ICBM #15), the left cerebral peduncle (ICBM #16), the right sagittal stratum (ICBM #21,29,31,47), the left sagittal stratum (ICBM #22,30,32,48), the right superior longitudinal fascicle (ICBM #41), the left superior longitudinal fascicle (ICBM #42), the anterior limb of the right internal capsule (ICBM #17), the anterior limb of the left internal capsule (ICBM #18), the posterior limb of the right internal capsule (ICBM #19), the posterior limb of the left internal capsule (ICBM #20), the right external capsule (ICBM #33), the left external capsule (ICBM #34), the right radiate crown (ICBM #23,25,27), the left radiate crown (ICBM #24,26,28).

### Claim 11 (depends on 8)

The method as claimed in claim 8, wherein the measurement of fractional anisotropy is performed on an MRI image of a patient having suffered a cerebral lesion, including cranial trauma, aneurismal meningeal hemorrhage, ischemic and intraparenchymal hemorrhagic accidents, cerebral anoxia.

### Claim 12 (depends on 8)

The method as claimed in claim 8, wherein the measurement of FA1 is performed on an MRI image taken in a period of 48 h to 31 days following the cerebral lesion.

### Claim 13 (depends on 8)

The method as claimed in claim 8, wherein the measurement of FA2 is performed on an MRI image taken in a period of at least one month following the measurement of FA1.